Tailored Light Therapy for Dementia

Recruiting at5 trial locations

Overseen by Mariana G Figueiro, PhD

Age: 65+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Icahn School of Medicine at Mount Sinai

Trial Summary

What is the purpose of this trial?

Tailored light treatment will increase sleep efficiency, reduce depression and reduce agitation scores in those with Alzheimer's disease and related dementia

Research Team

Mariana G Figueiro, PhD

Principal Investigator

Icahn School of Medicine at Mount Sinai

Eligibility Criteria

This trial is for individuals with mild to moderate Alzheimer's disease and related dementia. It's not suitable for those who are blind, have major organ failure or illness, a history of head injury, uncontrolled hypertension or diabetes, use sleep aid medicine, or have obstructing cataracts or macular degeneration.

Inclusion Criteria

I have been diagnosed with mild to moderate Alzheimer's or related dementia.

Exclusion Criteria

My major organs are functioning properly.

I have macular degeneration.

I have had a head injury in the past.

Treatment Details

Interventions

• Tailored Light Treatment (Behavioural Intervention)

Trial Overview The study tests whether tailored light treatment can improve sleep efficiency, reduce depression symptoms, and lessen agitation in people with dementia. Participants will receive either an active light intervention designed just for them or a placebo-like inactive one.

Participant Groups

Group I: Active Intervention Active Control 1 Intervention

Light levels, primary and secondary measurements are obtained after a 4-week intervention period where active lighting is experienced by patients.

Group II: Inactive intervention Placebo Group 1 Intervention

Light levels, primary and secondary measurements are obtained after a 4-week intervention period where an inactive lighting is experienced by patients

Who Is Running the Clinical Trial?

Icahn School of Medicine at Mount Sinai

Lead Sponsor

Trials

933

Recruited

579,000+

Dr. Brendan Carr

Icahn School of Medicine at Mount Sinai

Chief Executive Officer since 2024

MD, MA, MS

Dr. Vicki LoPachin

Icahn School of Medicine at Mount Sinai

Chief Medical Officer

MD, FACP, MBA

National Institute on Aging (NIA)

Collaborator

Trials

1,841

Recruited

28,150,000+

Dr. Richard J. Hodes

National Institute on Aging (NIA)

Chief Executive Officer since 1993

MD from Harvard Medical School

Dr. Marie Bernard

National Institute on Aging (NIA)

Chief Medical Officer

MD from Harvard Medical School